StockData
West Pharmaceutical Services Inc logo

West Pharmaceutical Services Inc (WST) KPIs and segments

WSTNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3031% above fair value
$404.02−10.10 (-2.44%)

Close on Nov 18, 2026Market cap $28.14BP/E 45.3Yield 0.21%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của West Pharmaceutical Services · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của West Pharmaceutical Services: 59 chỉ số vận hành, trong đó có Consolidated Net Sales, Proprietary Products Segment Net Sales và West Vantage Segment Net Sales, lấy từ 219 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Proprietary Products($M)
729723694662648620563614601560560594
West Vantage($M)
146150151157147135
Contract-Manufactured Products($M)
143157147135135146142136138
Proprietary Products($M)
231212189190175162131162158131126164
West Vantage($M)
15.512.915.622.317.813.5
Contract-Manufactured Products($M)
9.8022.317.813.516.221.817.217.118.8
Proprietary Products($M)
323308273286264248210251236207207
West Vantage($M)
2421.223.330.325.621.7
Contract-Manufactured Products($M)
18.230.325.621.722.9292323.1
West Vantage($M)
-8.20-5.10-5.60-13.6-25.5-18.1
Contract-Manufactured Products($M)
-18.3-13.6-25.5-18.1-24.2-30-39.2-27.6
Proprietary Products($M)
-28.6-35.4-36.5-56.2-47.7-48.5-51.9-79.1-47.8-58.5-61.1
Proprietary Products($M)
2,9252,9092,9322,9872,9892,8292,6252,6212,629
Contract-Manufactured Products($M)
718686668628612528
West Vantage($M)
697718740718
Consolidated Net Sales($M)7
875872845805805767698749747702695732
Consolidated Organic Net Sales Growth (Constant Currency & Ex-Divestitures)(%)
11.9%12.7%15.3%3.3%5.0%6.8%2.1%3.3%-0.5%-5.9%-3.0%1.4%
Consolidated Reported Net Sales Growth (YoY)(%)
8.7%13.8%21.0%7.5%7.7%9.2%0.4%2.3%-0.1%-6.9%-3.0%3.3%
Consolidated Organic Net Sales (Non-GAAP Constant Currency)($M)
867775750710756744708692714
Consolidated Foreign Currency Translation Impact($M)
-416.5-11.7-7.202.90-6.103.4018.5
Consolidated Foreign Currency Translation Impact (YoY %)(%)
1.1%5.7%4.2%2.7%
Quarterly Consolidated Revenue Bridge: Volume and Mix Contribution($M)
58.36782.73844.1
Quarterly Consolidated Revenue Bridge: Sales Price Contribution($M)
33.630.324.211.712.5
Proprietary Products Segment Net Sales($M)10
729723694662648620563614601560560594
Proprietary Products Organic Net Sales Growth(%)
16.6%15.5%17.5%3.6%5.1%8.4%2.4%4.5%-0.5%-8.4%-4.0%-0.3%
Proprietary Products Reported Net Sales Growth(%)
12.6%16.6%23.3%7.8%7.7%10.7%0.6%-0.2%-9.4%-4.0%1.5%
Proprietary Products Organic Net Sales (Non-GAAP Constant Currency)($M)
720618607573620599565557578
Proprietary Products Foreign Currency Translation Impact($M)
-312.9-9.70-6.502.20-5.402.8015.7
Proprietary Products Foreign Currency Translation Impact (YoY %)(%)
1.1%5.8%4.2%2.6%
Proprietary Products Share of Consolidated Net Sales(%)
83.0%82.0%82.0%80.0%
High-Value Products (HVP) Share of Proprietary Products Segment Sales (Legacy Disclosure)(%)
74.0%72.0%75.0%
High-Value Product (HVP) Components Net Sales($M)4
467424409390390355316324335
HVP Components Share of Consolidated Net Sales(%)
53.0%49.0%48.0%48.0%48.0%47.0%45.0%45.0%46.0%47.0%
HVP Components Organic Net Sales Growth(%)
20.3%18.4%22.6%15.1%13.3%
HVP Components Reported Net Sales Growth(%)
19.7%19.4%29.6%20.3%16.3%
HVP Components Foreign Currency Impact (YoY %)(%)
1.0%7.0%5.2%3.0%
High-Value Product (HVP) Delivery Devices Net Sales($M)4
99.113112411099.110195.8133118
HVP Delivery Devices Share of Consolidated Net Sales(%)
11.0%15.0%15.0%12.0%13.0%14.0%20.0%23.0%22.0%
HVP Delivery Devices Organic Net Sales Growth(%)
26.4%29.2%27.5%-18.1%-16.7%
HVP Delivery Devices Reported Net Sales Growth(%)
0.0%29.6%29.0%-16.9%-15.7%
HVP Delivery Devices Foreign Currency Impact (YoY %)(%)
0.4%1.5%1.2%1.0%
Standard Packaging Net Sales($M)4
163167161162158163151157149
Standard Packaging Share of Consolidated Net Sales(%)
19.0%19.0%19.0%20.0%21.0%22.0%16.0%11.0%11.0%
Standard Packaging Organic Net Sales Growth(%)
3.1%0.7%0.5%-1.7%3.6%
Standard Packaging Reported Net Sales Growth(%)
2.9%2.4%6.7%3.0%6.7%
Standard Packaging Foreign Currency Impact (YoY %)(%)
1.7%6.2%4.7%3.1%
West Vantage (Contract-Manufactured Products) Segment Net Sales($M)6
146150151143157147135135146142136138
West Vantage Share of Consolidated Net Sales(%)
17.0%17.0%18.0%20.0%19.0%19.0%19.0%20.0%20.0%
West Vantage Organic Net Sales Growth(%)
-6.6%0.8%6.2%1.9%4.9%0.5%0.8%-2.0%0.0%5.4%1.3%9.4%
West Vantage Reported Net Sales Growth(%)
-7.3%2.0%11.6%6.2%8.0%3.0%-0.7%-2.5%4.9%1.8%11.6%
West Vantage Organic Net Sales (Non-GAAP Constant Currency)($M)
147157143137136145143135136
West Vantage Foreign Currency Translation Impact($M)
-13.60-2-0.700.70-0.700.602.80
West Vantage Foreign Currency Translation Impact (YoY %)(%)
1.2%5.4%4.3%3.1%
GLP-1 Franchise Share of Consolidated Net Sales(%)2
21.0%18.0%18.0%17.0%17.0%
GLP-1 Elastomers (Proprietary Products) Share of Consolidated Net Sales(%)
12.0%10.0%10.0%10.0%9.0%8.0%
GLP-1 Contract Manufacturing (West Vantage) Share of Consolidated Net Sales(%)
9.0%8.0%8.0%7.0%8.0%
Ongoing EU GMP Annex 1 / HVP Customer Upgrade Projects
325375370340
Biologics Market Unit Net Sales (Proprietary Products)($M)4
379375355340329288269305296
Biologics Share of Consolidated Net Sales(%)
43.0%43.0%42.0%42.0%41.0%38.0%39.0%40.0%36.0%37.0%
Biologics Organic Net Sales Growth(%)
23.2%29.2%25.9%7.3%8.3%
Biologics Reported Net Sales Growth(%)
15.3%30.3%31.6%11.5%11.0%
Biologics Foreign Currency Impact (YoY %)(%)
1.1%5.7%4.2%2.7%
Pharma Market Unit Net Sales (Proprietary Products)($M)4
221205211192183199181182174
Pharma Share of Consolidated Net Sales(%)
25.0%24.0%25.0%24.0%22.0%26.0%26.0%23.0%26.0%25.0%
Pharma Organic Net Sales Growth(%)
21.4%1.6%9.8%0.3%1.4%
Pharma Reported Net Sales Growth(%)
21.3%3.3%16.6%5.5%4.7%
Pharma Foreign Currency Impact (YoY %)(%)
1.7%6.8%5.2%3.3%
Generics Market Unit Net Sales (Proprietary Products)($M)4
128143129130136134113127131
Generics Share of Consolidated Net Sales(%)
15.0%16.0%15.0%17.0%17.0%16.0%18.0%18.0%18.0%
Generics Organic Net Sales Growth(%)
-4.5%6.7%9.8%-0.6%2.6%
Generics Reported Net Sales Growth(%)
-5.7%6.9%14.2%2.2%4.0%
Generics Foreign Currency Impact (YoY %)(%)
0.2%4.4%2.8%1.4%
Americas Net Sales($M)4
401389377359375350339355357
Americas Share of Consolidated Net Sales(%)
46.0%44.0%45.0%45.0%47.0%45.0%49.0%48.0%43.0%43.0%
Americas Organic Net Sales Growth(%)
12.4%10.6%10.8%0.7%5.2%
Americas Reported Net Sales Growth(%)
6.9%11.2%11.3%1.1%5.3%
Americas Foreign Currency Impact (YoY %)(%)
0.6%0.5%0.4%0.1%
Europe, Middle East & Africa (EMEA) Net Sales($M)4
376400399370361350307323330
EMEA Share of Consolidated Net Sales(%)
43.0%46.0%47.0%46.0%45.0%46.0%44.0%44.0%48.0%48.0%
EMEA Organic Net Sales Growth(%)
5.7%12.1%17.9%5.1%3.1%
EMEA Reported Net Sales Growth(%)
4.2%14.3%30.1%14.6%9.4%
EMEA Foreign Currency Impact (YoY %)(%)
2.2%12.2%9.5%6.3%
Asia Pacific Net Sales($M)4
97.183.868.276.268.267.152.27160.3
Asia Pacific Share of Consolidated Net Sales(%)
11.0%10.0%8.0%8.0%9.0%7.0%8.0%9.0%9.0%
Asia Pacific Organic Net Sales Growth(%)
41.9%27.0%29.3%8.3%14.9%
Asia Pacific Reported Net Sales Growth(%)
42.4%24.9%30.7%7.3%13.1%
Asia Pacific Foreign Currency Impact (YoY %)(%)
-2.1%1.4%-1.0%-1.8%
United States Net Sales1
United States Long-Lived Assets($M)
835832757
Germany Net Sales1
Germany Long-Lived Assets($M)
233191176
France Net Sales1
France Long-Lived Assets($M)
11384.778.5
Ireland Net Sales1
Ireland Long-Lived Assets($M)
366300207
Other European Countries Net Sales1
Other European Countries Long-Lived Assets($M)
10998.199.2
Other Countries Net Sales1
Other Countries Long-Lived Assets($M)
222210195
Proprietary Products Segment Gross Profit($M)2
323308273286264248210251236207207253
Proprietary Products Segment Gross Margin(%)
44.4%42.6%39.3%43.2%40.8%40.1%37.3%40.8%39.2%37.0%37.0%42.7%
Proprietary Products Cost of Goods Sold (ASU 2023-07 Segment Expense)($M)
405415421376384372353363366353352
Proprietary Products Segment Operating Profit($M)6
231212189190175162131162158131126164
Proprietary Products Segment Operating Margin(%)
31.6%29.3%27.3%28.7%27.1%
Proprietary Products Research and Development Expense($M)
18.319.715.821.817.119.116.318.515.517.517.6
Proprietary Products Selling, General and Administrative Expense($M)
74.569.56568.265.661.560.358.156.656.160.7
Proprietary Products Other Segment Expense (Income), Net($M)
06.903.1066.106311.85.402.402.50
Proprietary Products Depreciation and Amortization($M)
37.636.336.438.735.133.732.733.533.83330
Proprietary Products Capital Expenditures($M)
28.635.436.556.247.748.551.979.147.858.561.1
West Vantage Segment Gross Profit($M)2
2421.223.318.230.325.621.722.9292323.124.7
West Vantage Segment Gross Margin(%)
16.5%14.2%15.5%12.7%19.3%17.5%16.1%17.0%19.9%16.2%17.0%17.9%
West Vantage Cost of Goods Sold (ASU 2023-07 Segment Expense)($M)
122129127125127121113112117119113
West Vantage Segment Operating Profit($M)6
15.512.915.69.8022.317.813.516.221.817.217.118.8
West Vantage Segment Operating Margin(%)
10.6%8.6%10.4%6.8%14.2%
West Vantage Research and Development Expense($M)
00000000000
West Vantage Selling, General and Administrative Expense($M)
8.108.307.807.807.5077.607.106.706.206.20
West Vantage Other Segment Expense (Income), Net($M)
0.400-0.100.600.500.800.60-0.400.50-0.40-0.20
West Vantage Depreciation and Amortization($M)
7.509.2087.607.106.806.406.205.504.904.70
West Vantage Capital Expenditures($M)
8.205.105.6018.313.625.518.124.23039.227.6
Total Reportable Segment Operating Profit($M)8
246225205200198180144179180148143182
Corporate General and Unallocated Administrative Costs($M)
20.316.517.220.81916.817.811.414.317.515.4
Corporate Stock-Based Compensation Expense($M)
4.3010.96.606.708.407.401.304.305.104.305
Corporate Amortization of Acquisition-Related Intangible Assets($M)
00000.200.200.200.200.20
Corporate Restructuring, Severance and Related Charges($M)
6.301.501.401.402.501.6017.83-0.9000
Corporate Portfolio Divestiture and M&A Net Loss (Gain)($M)
-546.401.90000
Other Unallocated Corporate Operating Items($M)
-45.918.33.9015.42.501.60183.20-0.700.200.20-1
Corporate Capital Expenditures($M)
2.302.700.601.6021.201.301.603.502.501.90
Corporate Depreciation and Amortization($M)
0.800.700.800.700.800.900.9010.9010.90
Consolidated Adjusted Operating Profit (Non-GAAP)($M)5
222197181172170155125163161126123160
Consolidated Adjusted Operating Profit Margin (Non-GAAP)(%)
25.3%22.6%21.4%21.4%21.1%20.3%17.9%21.7%21.5%18.0%17.7%21.8%
Consolidated Adjusted Net Income (Non-GAAP)($M)
189169154148142134106133136112116137
Consolidated Adjusted Diluted Earnings Per Share (Non-GAAP)($)
2.662.372.132.041.961.841.451.821.851.521.561.83
Consolidated GAAP Gross Margin(%)
39.7%37.7%35.1%37.8%36.6%35.7%33.2%36.5%35.4%32.8%33.1%38.0%
Consolidated GAAP Operating Margin(%)
30.6%20.5%21.0%19.5%20.8%20.1%15.3%21.3%21.6%18.0%17.7%22.0%
Remaining Performance Obligations (Backlog) Expected Within 1 Year($M)1
40.142.158.44343.444.7
Remaining Performance Obligations (Backlog) Expected Beyond 1 Year($M)
3.603.603.804.302.803.10
Contract Liabilities (Customer Advances & Deferred Revenue)($M)2
43.745.762.247.346.247.853.852.257.9
Contract Assets (Unbilled Revenue)($M)
15.117.215.427.527.925.842.322.619.9
Prior-Year Contract Liabilities Recognized as Revenue($M)
23.118.315.5
Total Inventories($M)3
465447453438421389401419430
Inventories: Raw Materials($M)
170179173183174163170174174
Inventories: Work in Process($M)
95.493.810997.691.182.98081.181.6
Inventories: Finished Goods($M)
199175171157156143151164174
Property, Plant and Equipment, Gross($M)2
3,2663,2493,2233,2333,1783,0052,9912,8642,791
PP&E: Accumulated Depreciation($M)
1,5941,5621,5211,4921,4561,3741,4201,3701,343
Property, Plant and Equipment, Net($M)
1,6721,6861,7021,7411,7221,6321,5711,4941,449
Total Lease Cost($M)5
1211.911.29.5011.310.510.69.7010.18.9088.10
Operating Lease Cost($M)
87.307.206.206.906.806.606.106.406.105.605.30
Variable Lease Cost($M)
2.3032.501.802.902.502.902.702.501.901.901.10
Short-Term Lease Cost($M)
1.201.100.90110.700.800.600.800.600.501.70
Operating Leases: Weighted-Average Remaining Lease Term(năm)
8.28.38.36.16.27.98.58.69.4
Operating Leases: Weighted-Average Discount Rate(%)
4.8%4.7%4.7%4.0%4.0%4.1%3.8%4.0%3.6%
Common Shares Repurchased Under Share Repurchase Programs2
663,511538,5911,222,019002,312550,281173,246170,771509,336729,679512,262
Total Cost of Shares Repurchased($M)
23115729800.5013454.452.4187267177
Average Price Paid per Share Repurchased($)
348244223243306367366346
Carrying Value of Investments in Affiliated Companies($M)2
216208209221225212218198203
Equity-Method Investments Carrying Value (Primarily Daikyo Seiko, Ltd.)($M)
215207205214217205210
Non-Marketable Cost-Method Investments Carrying Value($M)
0.600.604.107.307.307.207.20
Equity in Net Income of Affiliated Companies (Daikyo Seiko & Mexico Affiliates)($M)
4.306.103.403.902.1053.4023.904.504.303.30
Related-Party Inventory & Component Purchases from Daikyo Seiko / Affiliates($M)1
3834.33439.525.230.227.726.430.124.928.624
Payables Due to Daikyo Seiko / Affiliated Companies($M)
34.227.227.519.824.825.624.820.426.7
Related-Party Sales to Daikyo Seiko / Affiliates($M)1
5.904.503.203.303.402.803.204.603.5043.202.70
Receivables Due from Daikyo Seiko / Affiliated Companies($M)
3.602.702.301.202.202.202.702.402.10
West & Medimop U.S. FDA 510(k) Premarket Device Clearances3
000000000100
West U.S. FDA Premarket Approvals (PMA)
000000000000
West U.S. FDA Medical Device Recalls
000000010000
West U.S. FDA Device Enforcement Actions
000000010000
West U.S. FDA MAUDE Medical Device Adverse Event Reports3
232022003100
MAUDE Reports: Device Malfunction
232022003100
MAUDE Reports: Patient Injury
000000000000
MAUDE Reports: Death
000000000000
U.S. MedTech Industry Total FDA 510(k) Clearances2
855923756806797886736856767793713877
U.S. MedTech Industry Total FDA PMA Approvals
565608567525585588524683538550459656
U.S. MedTech Industry Total FDA MAUDE Adverse Event Reports
1,189,467923,529811,618751,012819,444632,296685,251709,498699,798631,546586,309573,619
Cumulative ClinicalTrials.gov Studies Citing West / Daikyo / SmartDose / Crystal Zenith1
New ClinicalTrials.gov Studies Started
311212
U.S. PPI: Surgical and Medical Instrument Manufacturing (Index 1982=100)1
U.S. Census Quarterly Hospital Taxable Revenue($M)
47,89646,67446,83446,29545,37045,35845,28443,77843,50543,70943,264
Consolidated Revenue (Income Statement)($M)16
875872845805805767698749747702695732
Total Assets (Balance Sheet)($M)29
4,0614,0764,1104,2704,1063,9533,6183,6433,6753,4893,6023,830
Operating Cash Flow (Cash Flow Statement)($M)10
19012489.9251197177129190180165118239
Proprietary Products Segment Revenue (Historical Financial Statement Series)($M)1
729723694662648620563614601560560594
West Vantage / Contract-Manufactured Products Segment Revenue (Historical Financial Statement Series)($M)1
146150151143157147135135146142136138

7 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core Revenue & Operational Drivers (Groups 1–4): Decomposes West Pharmaceutical Services' revenue and operating performance across Proprietary Products (High-Value Product Components, HVP Delivery Devices, and Standard Packaging) and West Vantage (formerly Contract-Manufactured Products), by Market Unit (Biologics, Pharma, Generics), by Region and Country (Americas, EMEA, Asia Pacific; U.S., Germany, France, Ireland), plus GLP-1 revenue shares (total, elastomers, and contract manufacturing), EU GMP Annex 1 upgrade project counts, and ASU 2023-07 segment cost breakdowns (COGS, R&D, SG&A, D&A, CapEx).
  • Consolidated vs. Parent-Only / Subsidiary Assessment: West Pharmaceutical Services, Inc. files consolidated financial statements under U.S. GAAP (Form 10-K/10-Q) and does not file standalone parent-only Schedule I financial statements (restricted net assets of subsidiaries do not exceed 25% of consolidated net assets). Operations of West's 49%-owned Japanese affiliate Daikyo Seiko, Ltd. are captured directly from Note 6 disclosures in Group 6 (ownership stake, investment carrying value, equity in net income, and related-party purchases, sales, payables, and receivables).
  • Derived Period Splits: Where SEC filings report cumulative year-to-date (6M, 9M, or 12M FY) figures for quarterly flow items (such as Q4 income statement, segment, related-party, and cash flow figures), standalone quarters are derived strictly via Q2 = 6M − Q1, Q3 = 9M − 6M, and Q4 = full year − first nine months (FY − 9M).

Không hiện vì thiếu các kỳ gần đây (6)

  • Annual Packaging Components Manufactured (>40 billion / >41 billion / ~43 billion / ~45 billion units per year) — Disclosed only as approximate bounds ('more than 40 billion', 'over 41 billion') in Form 10-K and Corporate Sustainability Reports; excluded because bound approximations are not permitted.
  • Customer Drug Approvals Supported (% of FDA/EMA biologics and small-molecule approvals) — Disclosed only as marketing bounds ('more than 90%', 'nearly 100%') in investor presentations; excluded because bound approximations are not permitted.
  • Physical Production Capacity & Utilization by Manufacturing Plant (25 global sites) — West discloses total cleanroom/building square footage only at an aggregate narrative level and does not publish plant-level unit capacity or utilization rates.
  • Daikyo Seiko, Ltd. Full Standalone Financial Statements — Daikyo Seiko is a privately held Japanese company (49% owned by West); West discloses its equity-method income, carrying value, and related-party purchases/sales/balances in Note 6, but does not file separate standalone financial statements for Daikyo under Rule 3-09.
  • Employee Function Share by Segment (Proprietary Products 73%, Contract-Manufactured Products 17%) — Introduced for the first time in the FY2025 Form 10-K with only 1 annual period available; excluded until a second annual period is reported.
  • Country-Specific Gender Pay Gap Reports (Ireland & Brazil) — Only 1–2 standalone annual PDF snapshots published without a continuous multi-year table across all periods.

Dữ liệu cập nhật 2026-11-09.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của West Pharmaceutical Services

See a number that looks wrong?